Claims
- 1. A therapeutic treatment method for preventing loss of bone mass or increasing bone mass in an individual, the method comprising:
administering to the individual a therapeutically effective morphogen in an amount and for a time sufficient to prevent loss of or to increase bone mass in said individual.
- 2. A therapeutic treatment method for preventing loss of bone mass or for increasing bone mass in an individual, comprising:
administering an agent that stimulates in vivo the effective concentration of a naturally occurring morphogen in said individual sufficient to prevent loss of or to increase bone mass in said individual.
- 3. The method of claim 1 or 2 wherein said loss of bone mass results from a metabolic bone disease.
- 4. The method of claim 3 wherein said metabolic bone disease comprises osteoporosis or osteomalacia.
- 5. The method of claim 1 or 2 wherein said loss of bone mass results from an imbalance in bone resorption or bone formation.
- 6. The method of claim 1 or 2 wherein said loss of bone mass results from an imbalance of calcium or phosphate metabolism.
- 7. The method of claim 1 or 2 wherein said loss of bone mass results from a vitamin D imbalance in the individual.
- 8. The method of claim 1 or 2 wherein said loss of bone mass is nutritionally or hormonally induced.
- 9. The method of claim 4 wherein said osteoporosis is postmenopausal or senile osteoporosis.
- 10. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence sharing at least 70% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and 60A(fx).
- 11. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence sharing at least 80% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx), and 60A(fx).
- 12. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence having greater than 60% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
- 13. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence having greater than 65% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
- 14. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1), including allelic and species variants thereof.
- 15. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence defined by Generic Sequences 1, 2, 3, 4, 5 or 6 (Seq. ID Nos. 1, 2, 3, 4, 30 or 31).
- 16. The method of claim 1 or 2 wherein said morphogen comprises an amino acid sequence defined by OPX (Seq. ID No. 29).
- 17. A method for repairing defects in bone tissue microstructure, comp rising:
administering to an individual a therapeutically effective morphogen in an amount and for a time sufficient to repair defects in said microstructure.
- 18. A method for repairing defects in bone tissue microstructure, comprising:
administering an agent capable of stimulating in vivo the effective concentration of a naturally occurring morphogen sufficient to repair said defects.
- 19. The method of claim 17 or 18 wherein said defect is a fracture.
- 20. The method of claim 17 or 18 wherein said defect results from a metabolic bone disease.
- 21. The method of claim 20 wherein said metabolic bone disease comprises osteoporosis or osteomalacia.
- 22. A method for protecting an individual at risk for loss of bone mass, the method comprising:
providing to the individual a therapeutically effective morphogen in an amount and for a time sufficient to protect said individual from loss of bone mass.
- 23. A method for protecting an individual at risk for loss of bone mass, the method comprising:
providing to the individual an agent that stimulates in vivo a therapeutically effective concentration of a naturally occurring morphogen sufficient to protect said individual from loss of bone mass.
- 24. The method of claim 22 or 23 wherein said individual is a postmenopausal female.
- 25. The method of claim 22 or 23 wherein said individual is at risk for loss of bone mass as a result of senile osteoporosis.
- 26. The method of claim 22 or 23 wherein said individual is undergoing dialysis.
- 27. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence sharing at least 70% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and 60A(fx).
- 28. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence sharing at least 80% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx), and 60A(fx).
- 29. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence having greater than 60% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
- 30. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence having greater than 65% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
- 31. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1), including allelic and species variants thereof.
- 32. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence defined by Generic Sequences 1, 2, 3, 4, 5 or 6 (Seq. ID Nos. 1, 2, 3, 4, 30 or 31).
- 33. The method of claim 17, 18 or 22 wherein said morphogen comprises an amino acid sequence defined by OPX (Seq. ID No. 29).
- 34. The method of claims 1, 2, 17, 18, 22 or 23, wherein said morphogen or said morphogen-stimulating agent is provided to the individual by oral administration.
- 35. The method of claims 1, 2, 17, 18, 22 or 23, wherein said morphogen or morphogen-stimulating agent is provided to the individual by parenteral administration.
- 36. The method of claims 1, 17, or 22 wherein said morphogen is provided to said individual in association with a molecule capable of enhancing the solubility of said morphogen.
- 37. The method of claim 36 wherein said molecule comprises casein or part or all of the pro domain of a morphogen.
- 38. The method of claim 37 wherein said pro domain comprises part or all of the sequence described by residues 30 to 292 of Seq. ID No. 16.
- 39. The method of claims 1, 17, or 22 wherein said morphogen is provide to the individual in association with a molecule capable of targeting said morphogen to bone tissue.
- 40. The method of claim 39 wherein said targeting molecule comprises tetracycline, diphosphonates, or an antibody that binds specifically to a molecule on the surface of bone tissue cells.
- 41. The method of claims 2, 18 or 23-wherein said morphogen-stimulating agent is provided to the individual in association with a molecule capable of targeting said agent to morphogen-producing or morphogen-secreting tissue.
RELATION TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Ser. No. 09/170,936 filed Oct. 13, 1998, which is a continuation of U.S. Ser. No. 432,883, filed May 2, 1995, which is a continuation of U.S. Ser. No. 115,914 filed Sep. 1, 1993, which is a continuation of Ser. No. 923,780, filed Jul. 31, 1992, which is a continuation-in-part of U.S. Ser. No. 752,857, filed Aug. 30, 1991, now abandoned, which is a continuation-in-part of U.S. Ser. No. 667,274, filed Mar. 11, 1991, now abandoned.
Continuations (4)
|
Number |
Date |
Country |
Parent |
09170936 |
Oct 1998 |
US |
Child |
09952318 |
Sep 2001 |
US |
Parent |
08432883 |
May 1995 |
US |
Child |
09170936 |
Oct 1998 |
US |
Parent |
08115914 |
Sep 1993 |
US |
Child |
08432883 |
May 1995 |
US |
Parent |
07923780 |
Jul 1992 |
US |
Child |
08115914 |
Sep 1993 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
07752857 |
Aug 1991 |
US |
Child |
07923780 |
Jul 1992 |
US |
Parent |
07667274 |
Mar 1991 |
US |
Child |
07752857 |
Aug 1991 |
US |